title: Single-dose intravenous melphalan in advanced multiple myeloma.
abstract: Eight patients with progressive multiple myeloma were given an intermediate intravenous dose of melphalan (30 mg/m2). A response lasting 2-18 months was observed in 7 patients. The bone marrow toxicity was well acceptable and most courses could be given on an outpatient basis. Intermediate-dose intravenous melphalan may be considered an alternative for treatment of relapsing or progressive multiple myeloma, even if the patient has previously received oral melphalan.
authors.affiliation: Department of Medicine, Ostra Hospital, Gothenburg University, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Bäck
authors.forename: R
authors.initials: R
authors.lastname: Lindblad
authors.forename: S
authors.initials: S
authors.lastname: Rödjer
authors.forename: J
authors.initials: J
authors.lastname: Westin
mesh_terms: D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D008558:Melphalan